ClinicalTrials.gov
public full text
Public Domain
A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
The objectives of this study are to evaluate the glycemic efficacy, safety, and tolerability of ersodetug as add-on to standard of care (SOC) therapy for treatment of hypoglycemia in patients with Tumor Hyperinsulinism (Tumor HI).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- SITAgliptin Plus GLARgine to Glycemic Control in the Hospital Setting (SITAGLAR-H)#992851
- A Study Comparing Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus#1197403
- Basal-bolus Insulin Therapy Versus Standard Therapy for the Inpatient Management of Type 2 Diabetes: the IDA2 Study#992449
- Treatment of GLP-1 for Diabetic Bariatric Patients#1228894
- Treatment of Type 2 Diabetes With Long Acting Basal Insulin in Jordan#1261536
Record · ID 1453200
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive